OPNET TECHNOLOGIES INC (OPNT) [Rocket]

Overview

OPNET TECHNOLOGIES INC (OPNT)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
03/22/2021	GN	Opiant Pharmaceuticals Strengthens Board of Directors With Appointment of Seasoned Clinical Development Executive Lorianne Masuoka, M.D.
02/08/2021	GN	Opiant Pharmaceuticals Announces First Patient Dosed in Confirmatory Pharmacokinetic Study Assessing OPNT003, Nasal Nalmefene, for the Treatment of Opioi...
12/14/2020	GN	Opiant Pharmaceuticals Announces Additional $3.5 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program
12/10/2020	GN	Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing
12/07/2020	GN	Opiant Pharmaceuticals Announces Appointment of Biopharmaceutical Leader Craig A. Collard as Chairman to its Board of Directors
08/31/2020	GN	Opiant Pharmaceuticals to Participate at the 2020 Cantor Global Virtual Healthcare Conference
08/06/2020	GN	Opiant Pharmaceuticals Announces Second Quarter 2020 Financial Results and Corporate Update

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Mar-31-12	Mar-31-11	Mar-31-10	Mar-31-09	Mar-31-08	Mar-31-07	Mar-31-06	Mar-31-05
Revenues	172.7	148.0	126.3	122.9	101.3	95.1	76.1	64.2
Revenue growth	16.7%	17.1%	2.8%	21.2%	6.5%	25.0%	18.5%	13.8%
Cost of goods sold	38.7	32.8	32.0	31.3	26.2	20.5	17.8	13.9
Gross profit	134.1	115.2	94.3	91.6	75.2	74.6	58.3	50.3
Gross margin	77.6%	77.8%	74.7%	74.5%	74.2%	78.4%	76.6%	78.3%
Sales and marketing	55.4	48.7	43.2	42.5	39.4	34.1	26.3	22.8
Research and development	37.8	34.7	32.0	30.8	27.5	21.7	18.6	15.5
General and administrative	12.9	12.9	11.0	11.9	11.7	11.0	13.4	9.7
EBITA	30.1	20.9	9.9	6.4	-3.4	7.8	0.0	2.3
EBITA margin	17.4%	14.1%	7.9%	5.2%	-3.4%	8.2%	0.0%	3.6%
Amortization of intangibles	2.2	2.1	1.8
EBIT	27.9	18.8	8.1	6.4	-3.4	7.8	0.0	2.3
EBIT margin	16.2%	12.7%	6.4%	5.2%	-3.4%	8.2%	0.0%	3.6%
Pre-tax income	27.8	18.7	8.0	7.7	0.2	11.6	2.6	3.7
Income taxes	9.5	6.3	2.2	2.9	-0.4	3.7	0.5	1.6
Tax rate	34.1%	33.5%	27.5%	38.2%		31.5%	19.2%	44.5%
Net income	18.3	12.4	5.8	4.7	0.5	8.0	2.1	2.1
Net margin	10.6%	8.4%	4.6%	3.9%	0.5%	8.4%	2.8%	3.2%

Diluted EPS	$0.81	$0.56	$0.28	$0.23	$0.03	$0.38	$0.10	$0.10
Shares outstanding (diluted)	22.7	22.1	20.8	20.5	20.6	21.2	20.6	20.6

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.